SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Kadmon Reports Topline Results From Primary Analysis Of ROCKstar In Patients With Chronic Graft vs Host Disease: Overall Response Rates 73% For 200 mg QD, 74% For 200mg BID

Benzinga · 05/21/2020 11:35